Arrowhead CEO breaks down drug partnerships with Johnson & Johnson and Amgen

Jim Cramer chats with Arrowhead Pharmaceuticals CEO Christopher Anzalone about projects the company is working on to silence genes that cause rare genetic disorders.
06:46
Thu, Oct 17 20197:08 PM EST